AU2013224832A1 - Test for diagnosing resistance to azacitidine - Google Patents

Test for diagnosing resistance to azacitidine Download PDF

Info

Publication number
AU2013224832A1
AU2013224832A1 AU2013224832A AU2013224832A AU2013224832A1 AU 2013224832 A1 AU2013224832 A1 AU 2013224832A1 AU 2013224832 A AU2013224832 A AU 2013224832A AU 2013224832 A AU2013224832 A AU 2013224832A AU 2013224832 A1 AU2013224832 A1 AU 2013224832A1
Authority
AU
Australia
Prior art keywords
bcl2l10
azacitidine
patient
protein
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013224832A
Other languages
English (en)
Other versions
AU2013224832A8 (en
Inventor
Patrick AUBERGER
Thomas Cluzeau
Frederic Luciano
Guillaume Robert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Nice Sophia Antipolis UNSA
Centre Hospitalier Universitaire de Nice
Original Assignee
Ct Hospitalier Universitaire Nice
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Nice Sophia Antipolis UNSA
Centre Hospitalier Universitaire de Nice
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Hospitalier Universitaire Nice, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Nice Sophia Antipolis UNSA, Centre Hospitalier Universitaire de Nice filed Critical Ct Hospitalier Universitaire Nice
Publication of AU2013224832A1 publication Critical patent/AU2013224832A1/en
Publication of AU2013224832A8 publication Critical patent/AU2013224832A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
AU2013224832A 2012-02-28 2013-02-28 Test for diagnosing resistance to azacitidine Abandoned AU2013224832A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1200584A FR2987446B1 (fr) 2012-02-28 2012-02-28 Test diagnostic de la resistance a l'azacitidine
FR12/00584 2012-02-28
PCT/FR2013/000055 WO2013128089A1 (fr) 2012-02-28 2013-02-28 Test diagnostic de la résistance à l'azacitidine

Publications (2)

Publication Number Publication Date
AU2013224832A1 true AU2013224832A1 (en) 2014-10-16
AU2013224832A8 AU2013224832A8 (en) 2014-11-13

Family

ID=48083449

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013224832A Abandoned AU2013224832A1 (en) 2012-02-28 2013-02-28 Test for diagnosing resistance to azacitidine

Country Status (11)

Country Link
US (1) US20150094217A1 (https=)
EP (1) EP2820417A1 (https=)
JP (1) JP6273552B2 (https=)
CN (1) CN104321649A (https=)
AU (1) AU2013224832A1 (https=)
BR (1) BR112014021173A2 (https=)
CA (1) CA2865684A1 (https=)
FR (1) FR2987446B1 (https=)
IL (1) IL234332A0 (https=)
IN (1) IN2014MN01795A (https=)
WO (1) WO2013128089A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2638400T3 (es) * 2014-03-27 2017-10-20 Palacky University, Olomouc Método de predicción de la respuesta tumoral a inhibidores de la metilación del ADN y regímenes terapéuticos alternativos para superar la resistencia
FR3048698B1 (fr) 2016-03-11 2021-03-05 Univ Claude Bernard Lyon Inhibiteurs de l'interaction bcl2 l10 / recepteur ip3
WO2019077080A1 (en) * 2017-10-19 2019-04-25 Universite Claude Bernard Lyon 1 ASSESSING THE RISK OF METASTATIC RECHUTE IN PATIENTS WITH BREAST CANCER
CN114874987A (zh) * 2022-03-01 2022-08-09 洛阳市中心医院（郑州大学附属洛阳中心医院） 一种骨髓异常增生综合征耐药细胞模型及其构建方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1715041A4 (en) * 2004-02-13 2007-12-19 Bml Inc METHOD FOR DETECTION OF A CANCER CELL OBTAINING A DRUG RESISTANT
CA2563074C (en) 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US20100099109A1 (en) * 2008-10-17 2010-04-22 Nodality, Inc., A Delaware Corporation Methods for Analyzing Drug Response
CN101632643A (zh) * 2009-08-18 2010-01-27 杭州咸达医药科技有限公司 阿扎胞苷冻干粉针制剂及其制备方法
JP5190477B2 (ja) * 2010-02-22 2013-04-24 譲治 稲澤 カンプトテシン類の制癌剤に対する薬剤耐性を獲得した肺癌細胞の検出方法
JP6219164B2 (ja) * 2010-05-27 2017-10-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 患者の子宮内膜の受容性を評価するための方法

Also Published As

Publication number Publication date
IL234332A0 (en) 2014-10-30
CA2865684A1 (fr) 2013-09-06
EP2820417A1 (fr) 2015-01-07
FR2987446B1 (fr) 2016-01-01
FR2987446A1 (fr) 2013-08-30
WO2013128089A1 (fr) 2013-09-06
BR112014021173A2 (pt) 2017-08-22
JP2015513369A (ja) 2015-05-11
IN2014MN01795A (https=) 2015-07-03
JP6273552B2 (ja) 2018-02-07
CN104321649A (zh) 2015-01-28
AU2013224832A8 (en) 2014-11-13
US20150094217A1 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
Linger et al. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer
Cervello et al. Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells
Nie et al. Morin inhibits proliferation and induces apoptosis by modulating the miR-188-5p/PTEN/AKT regulatory pathway in CML cells
Taha-Mehlitz et al. Adenylosuccinate lyase is oncogenic in colorectal cancer by causing mitochondrial dysfunction and independent activation of NRF2 and mTOR-MYC-axis
AU2017315459A1 (en) Methods of treating fibroblast growth factor 19-mediated cancers and tumors
EP3022222A1 (en) Differential bh3 mitochondrial profiling
Faria et al. Progression in myeloid neoplasms: beyond the myeloblast
Singh et al. Non‐canonical cMet regulation by vimentin mediates Plk1 inhibitor–induced apoptosis
Wang et al. Filamin A regulates EGFR/ERK/Akt signaling and affects colorectal cancer cell growth and migration
Stern et al. Potential role of the bitter taste receptor T2R14 in the prolonged survival and enhanced chemoresponsiveness induced by apigenin
AU2013224832A1 (en) Test for diagnosing resistance to azacitidine
Zhang et al. Melatonin-mediated cGAS-STING signal in senescent macrophages promote TNBC chemotherapy resistance and drive the SASP
AU2014382143B2 (en) Anticancer adjuvant composition containing RIP3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting RIP3 expression, and method for monitoring sensitivity of anticancer drug
Park et al. Pan-RAF inhibitor LY3009120 is highly synergistic with low-dose cytarabine, but not azacitidine, in acute myeloid leukemia with RAS mutations
EP2906952A1 (en) Sialyltransferase st3gal6 as a marker for multiple myeloma
Cagliero et al. Reversal of multidrug-resistance using Valspodar®(PSC 833) and doxorubicin in osteosarcoma
Phillips et al. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma
US11674184B2 (en) Enhancing radiation sensitivity comprising administering PMVK inhibiting siRNA and shRNA
JP2013522613A (ja) 化学療法に対する応答性を予測するための方法
Co et al. Schisandrin B suppresses colon cancer growth by inducing cell cycle arrest and apoptosis via the CHOP signalling pathway
Kurogi et al. Annexin A8 drives MEK inhibitor resistance, providing a druggable target for pancreatic ductal adenocarcinoma
Yunianto In vitro studies targeting the JAK/STAT pathway in a microenvironment that simulates ovarian cancer
Varughese Impact of therapy induced senescence in cancerous and non-cancerous cells
Jezierska et al. Is urinary type IV collagen a good marker of early impairment of renal function in childhood cancers survivors?
Chidambara et al. Pathogen concentration integrated molecular analysis for SMARTDIAGNOS: the next generation sepsis diagnosis

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 28 , NO 41 , PAGE(S) 5579 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME CENTRE HOSPITALIER UNIVERSITAIRE DE NICE; UNIVERSITE NICE SOPHIA ANTIPOLIS; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, APPLICATION NO. 2013224832, UNDER INID (71) CORRECT THE CO-APPLICANT NAME TO INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period